Millennium Research Group's Marketrack Results find Botulinum Toxin has
Higher 2007 Market Share in Canada than in the US
WALTHAM, Mass., Jan. 31 /PRNewswire/ -- Millennium Research Group's (MRG's) Facial Aesthetic Marketrack results indicate that revenue and usage share of botulinum toxin (as a percentage of all injectables) was consistently higher in Canada than in the United States throughout 2007. With the revenue share of botulinum toxin nearly 10% higher in Canada, botulinum toxin was preferred more in Canada than it was in the US in 2007.
In Canada, dermal fillers, including hyaluronic acid (HA), collagen, and particle and polymer fillers, had a usage share approximately equal to that of botulinum toxin. In contrast, the US injectable market was dominated by dermal fillers, which represented approximately two-thirds of total facial injectables units used. Throughout 2007, the Canadian market was driven by widespread public awareness of botulinum toxin cosmetic and other advertised dermal fillers, including HA, collagen, and particle and polymer fillers. As a result, well-informed patients have been asking for injectables such as Allergan's Botox by name. Media exposure will likely not only encourage first-time patients to try Botox injections, but will also encourage existing patients to continue with their treatments.
"An increase in marketing on Allergan's behalf has had a big effect on this increase in Canada," says Jennifer Thomas, Senior Analyst at Millennium Research Group. "Media such as magazines and television shows frequently profile cosmetic procedures, which has led to increased public awareness and widespread acceptance of various less invasive aesthetic treatments."
MRG provides a number of products focused on the global facial
aesthetics market. For ongoing quarterly tracking of market shares by
brand, MRG offers its Marketrack service, which tracks facial aesthetic
products -- such as botulinum t
|SOURCE Millennium Research Group|
Copyright©2008 PR Newswire.
All rights reserved